Masimo Q1 2023 revenue $565M (+85.7% YoY), healthcare up 14%; non-GAAP EPS $0.87 beats; FY guidance raised

MASIMO CORP

2023-Q1 EPS reported $0.39 revenue$565,000,000

Consolidated revenue $565.0M (+85.7% YoY); healthcare $346.7M (+14.0% reported, +15.8% constant currency).
Non-healthcare (consumer) revenue $218.3M; GAAP EPS $0.39, non-GAAP EPS $0.87.
Full-year 2023 guidance: consolidated revenue $2,415-2,460M; non-GAAP EPS $4.70-4.80.
CEO cites solid performance, new hospital wins, and momentum in consumer health (Opioid Halo, Stork, Freedom pre-order).
Healthcare growth driven by rainbow, Nomoline, Sedline, O3 monitoring uptake.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MASIMO CORP reported first quarter of 2023 results: revenue $565.0 million, net income $21.3 million, EPS $0.39 per diluted share. Guidance reaffirmed.

Period: first quarter of 2023
Revenue: $565.0 million
Net income: $21.3 million
EPS: $0.39 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

asimo Reports First Quarter 2023 Financial Results First Quarter 2023 Highlights • Consolidated revenue was $565.0 million; • Healthcare revenue was $346.7 million, representing 14.0% reported growth and 15.8% constant currency growth; • Non-healthcare revenue was $218.3 million; • GAAP earnings per diluted share was $0.39; and • Non-GAAP earnings per diluted share was $0.87.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

MASIMO CORP filing history →

Source: SEC EDGAR

accession 0000937556-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.